Effects of LOTRIGA in chronic heart failure patients with hyperlipidemia: a prospective randomized, open-label, parallel group comparison study

Trial Profile

Effects of LOTRIGA in chronic heart failure patients with hyperlipidemia: a prospective randomized, open-label, parallel group comparison study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary)
  • Indications Chronic heart failure; Hyperlipidaemia
  • Focus Therapeutic Use
  • Acronyms EPA/DHA
  • Most Recent Events

    • 16 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top